Johnson & Johnson (JNJ) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

JNJ Johnson & Johnson

Watchlist

144.750
-1.660-1.13%

Close Dec 18 16:00 ET

144.750
0.0000.00%

Post 20:02 ET

348.50BMarket Cap23.54P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Kevin Travers16:16 ET
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Moomoo 24/715:35 ET
Dow's Drop: How Blue-chips Have Fared During Index's Peak Turned Worst-run in Decades
Seeking Alpha11:09 ET
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Kevin Travers11:03 ET
Least Shorted S&P 500 Stocks in November
Seeking AlphaDec 18 10:37 ET
Express News | J&J: Application to EMA for New Indication Approval for Imbruvica in Adults With Previously Untreated Mcl Eligible for Autologous Stem Cell Transplant
ReutersDec 18 07:51 ET

Comments

KyleyW

Dec 16 12:06

$Johnson & Johnson (JNJ.US)$ how low can it drop? below 140? i wanted to enter

10xStockPicks

Dec 15 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

10xStockPicks

Dec 14 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...